
John McKearn, Arch Oncology chairman
Scoop: Roche-backed startup gives up on CD47, lays off all employees
Arch Oncology ended its work on developing an anti-CD47 antibody and most employees have left the company, Endpoints News has learned.
The Brisbane, CA, and St. Louis biotech scrapped clinical development of the antibody, dubbed AO-176, according to an automatic reply email from a former clinical operations director.
All Arch employees were let go and the company “was in a wind-down situation,” according to the LinkedIn bio of Arch’s former VP of human resources.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters